Treatment of Acute COPD Exacerbation
(See also Chronic Obstructive Pulmonary Disease.)
COPD management involves treatment of chronic stable disease and treatment of exacerbations.
Treatment of acute exacerbations involves
The immediate objectives are to ensure adequate oxygenation and near-normal blood pH, reverse airway obstruction, and treat any cause.
The cause of an acute exacerbation is usually unknown, although some acute exacerbations result from bacterial or viral infections. Smoking, irritative inhalational exposure, and high levels of air pollution also contribute.
Mild exacerbations often can be treated on an outpatient basis in patients with adequate home support. Elderly, frail patients and patients with comorbidities, a history of respiratory failure, or acute changes in ABG measurements are admitted to the hospital for observation and treatment. Patients with life-threatening exacerbations manifested by uncorrected moderate to severe acute hypoxemia, acute respiratory acidosis, new arrhythmias, or deteriorating respiratory function despite hospital treatment should be admitted to the ICU and their respiratory status monitored frequently.
Most patients require oxygen supplementation during a COPD exacerbation, even those who do not need it chronically. Hypercapnia may worsen in patients given oxygen. This worsening has traditionally been thought to result from an attenuation of hypoxic respiratory drive. However, increased ventilation/perfusion (V/Q) mismatch probably is a more important factor.
Before oxygen administration, pulmonary vasoconstriction minimizes V/Q mismatch by decreasing perfusion of the most poorly ventilated areas of the lungs. Increased V/Q mismatch occurs because oxygen administration attenuates this hypoxic pulmonary vasoconstriction.
The Haldane effect may also contribute to worsening hypercapnia, although this theory is controversial. The Haldane effect is a decrease in Hb’s affinity for carbon dioxide, which results in increased amounts of carbon dioxide dissolved in plasma. Oxygen administration, even though it may worsen hypercapnia, is recommended; many patients with COPD have chronic as well as acute hypercapnia and thus severe CNS depression is unlikely unless Paco2 is > 85 mm Hg. The target level for Pao2 is about 60 mm Hg; higher levels offer little advantage and increase the risk of hypercapnia.
Oxygen is given via Venturi mask so it can be closely regulated, and the patient is closely monitored. Patients whose condition deteriorates with oxygen therapy (eg, those with severe acidemia or CNS depression) require ventilatory assistance.
Many patients who require home oxygen for the first time when they are discharged from the hospital after an exacerbation improve within 30 days and no longer require oxygen. Thus, the need for home oxygen should be reassessed 60 to 90 days after discharge.
Noninvasive positive-pressure ventilation (eg, pressure support or bilevel positive airway pressure ventilation by face mask) is an alternative to full mechanical ventilation. Noninvasive ventilation appears to decrease the need for intubation, reduce hospital stay, and reduce mortality in patients with severe exacerbations (defined as a pH < 7.30 in hemodynamically stable patients not at immediate risk of respiratory arrest).
Noninvasive ventilation appears to have no effect in patients with less severe exacerbation. However, it may be indicated for patients with less severe exacerbations whose ABGs worsen despite initial drug or oxygen therapy or who appear to be imminent candidates for full mechanical ventilation but who do not require intubation for control of the airway or sedation for agitation. Patients who have severe dyspnea, hyperinflation, and use of accessory muscles of respiration may also gain relief from positive airway pressure. Deterioration while receiving noninvasive ventilation necessitates invasive mechanical ventilation.
Deteriorating ABG values, deteriorating mental status, and progressive respiratory fatigue are indications for endotracheal intubation and mechanical ventilation. Ventilator settings, management strategies, and complications are discussed elsewhere. Risk factors for ventilatory dependence include an FEV1< 0.5 L, stable ABGs with a Pao2 < 50 mm Hg, or a Paco2 > 60 mm Hg, severe exercise limitation, and poor nutritional status. Therefore, if patients are at high risk, discussion of their wishes regarding intubation and mechanical ventilation should be initiated and documented (see Advance Directives) while they are stable outpatients. However, overconcern about possible ventilator dependence should not delay management of acute respiratory failure; many patients who require mechanical ventilation can return to their pre-exacerbation level of health. High-flow nasal oxygen therapy has also been tried for patients with acute respiratory failure due to a COPD exacerbation and would be considered experimental at this time.
In patients who require prolonged intubation (eg, > 2 wk), a tracheostomy is indicated to facilitate comfort, communication, and eating. With a good multidisciplinary pulmonary rehabilitation program, including nutritional and psychologic support, many patients who require prolonged mechanical ventilation can be successfully removed from a ventilator and can return to their former level of function. Specialized programs are available for patients who remain ventilator-dependent after acute respiratory failure. Some patients can remain off the ventilator during the day. For patients with adequate home support, training of family members can permit some patients to be sent home with ventilators.
Beta-agonists and anticholinergics, with or without corticosteroids, should be started concurrently with oxygen therapy (regardless of how oxygen is administered) with the aim of reversing airway obstruction. Methylxanthines, once considered essential to treatment of acute COPD exacerbations, are no longer used; toxicities exceed benefits.
Short-acting beta-agonists are the cornerstone of drug therapy for acute exacerbations. The most widely used drug is albuterol 2.5 mg by nebulizer or 2 to 4 puffs (100 mcg/puff) by metered-dose inhaler q 2 to 6 h. Inhalation using a metered-dose inhaler causes rapid bronchodilation; there are no data indicating that doses taken with nebulizers are more effective than the same doses correctly taken with metered-dose inhalers. In cases of severe unresponsive bronchospasm, continuous nebulizer treatments may sometimes be administered.
Ipratropium, an anticholinergic, is effective in acute COPD exacerbations and should be given concurrently or alternating with beta-agonists. Dosage is 0.25 to 0.5 mg by nebulizer or 2 to 4 inhalations (17 to 18 mcg of drug delivered per puff) by metered-dose inhaler q 4 to 6 h. Ipratropium generally provides bronchodilating effect similar to that of usual recommended doses of beta-agonists.
The role of the longer-acting anticholinergic drugs in treating acute exacerbations has not been defined.
Corticosteroids should be begun immediately for all but mild exacerbations. Options include prednisone 30 to 60 mg po once/day for 5 days or tapered over 7 to 14 days and methylprednisolone 60 to 500 mg IV once/day for 3 days and then tapered over 7 to 14 days. Alternatively, a 5-day course of 40 mg of prednisone appears to be equally effective. These drugs are equivalent in their acute effects; inhaled corticosteroids have no role in the treatment of acute exacerbations.
Antibiotics are recommended for exacerbations in patients with purulent sputum. Some physicians give antibiotics empirically for change in sputum color or for nonspecific chest x-ray abnormalities. Routine cultures and Gram stains are not necessary before treatment unless an unusual or resistant organism is suspected (eg, in hospitalized, institutionalized, or immunosuppressed patients). Drugs directed against oral flora are indicated. Examples of antibiotics that are effective and inexpensive are
These antibiotics are given for 7 to 14 days. Choice of drug is dictated by local patterns of bacterial sensitivity and patient history.
When patients are seriously ill or clinical evidence suggests that the infectious organisms are resistant, broader spectrum 2nd-line drugs can be used. These drugs include amoxicillin/clavulanate 250 to 500 mg po tid, fluoroquinolones (eg, ciprofloxacin, levofloxacin), 2nd-generation cephalosporins (eg, cefuroxime, cefaclor), and extended-spectrum macrolides (eg, azithromycin, clarithromycin). These drugs are effective against beta-lactamase–producing strains of H. influenzae and M. catarrhalis but have not been shown to be more effective than first-line drugs for most patients.
Patients can be taught to recognize a change in sputum from normal to purulent as a sign of impending exacerbation and to start a 10- to 14-day course of antibiotic therapy. Long-term antibiotic prophylaxis is recommended only for patients with underlying structural changes in the lung, such as bronchiectasis or infected bullae. In patients with frequent exacerbations, long-term macrolide use reduces exacerbation frequency but may have adverse effects.
Antitussives, such as dextromethorphan and benzonatate, have little role.
Opioids (eg, codeine, hydrocodone, oxycodone) should be used judiciously for relief of symptoms (eg, severe coughing paroxysms, pain) insofar as these drugs may suppress a productive cough, impair mental status, and cause constipation.
With very severe disease exercise is unwarranted and activities of daily living are arranged to minimize energy expenditure. For example, patients may arrange to live on one floor of the house, have several small meals rather than fewer large meals, and avoid wearing shoes that must be tied. End-of-life care should be discussed, including whether to pursue mechanical ventilation, the use of palliative sedation, and appointment of a surrogate medical decision-maker in the event of the patient’s incapacitation.
Most patients require oxygen supplementation during an exacerbation.
Inhaled short-acting beta-agonists are the cornerstone of drug therapy for acute exacerbations.
Use antibiotics if patients have acute exacerbations and purulent sputum.
For patients with end stage COPD, address end-of-life care proactively, including preferences regarding mechanical ventilation and palliative sedation.
Drug NameSelect Trade
levofloxacinIQUIX, LEVAQUIN, QUIXIN
TrimethoprimNo US brand name